Lederfolat Anwendung Bei Erwachsenen Und Kindern (Calcium Folinate Pentahydrate)

Calcium folinate is converted to folinic acid, the reduced form of folic acid. It bypasses the block created by drugs such as methotrexate on dihydrofolate reductase, restoring the cellular pool of tetrahydrofolate needed for DNA synthesis and repair.

The dose of Lederfolat is determined by the prescribing clinician based on the specific indication, patient age, weight, renal function and concurrent therapies. Only a qualified health‑care professional should set the regimen.

Safety in pregnancy and lactation has not been fully established. It should be used only if the potential benefit outweighs any possible risk, and the decision should be made in consultation with an obstetrician or maternal‑fetal medicine specialist.

Enquiries are submitted through the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike standard folic acid, calcium folinate is already in the reduced, biologically active form, allowing it to bypass dihydrofolate reductase inhibition. This makes it effective for methotrexate rescue, whereas regular folic acid does not provide the same rapid cellular protection.

Store Lederfolat at below 25 °C in its original container, protecting it from moisture, heat and direct light. Do not store in a bathroom or near a kitchen stove, and keep the package tightly closed when not in use.

Lederfolat is supplied as an oral formulation. It is taken by mouth with or without food, according to the prescribing clinician’s instructions. The tablet should be swallowed whole and not crushed unless specifically directed.

Serious risks include severe allergic reactions such as anaphylaxis, neutropenia, hepatic dysfunction and renal impairment. Patients should be monitored for signs of these conditions, and treatment should be stopped immediately if they occur.

Lederfolat should be avoided in individuals with known hypersensitivity to calcium folinate or other folate analogs, and it should be used with caution in patients with severe renal or hepatic impairment. Pregnant or breastfeeding women should only use it when clearly indicated by a physician.